169 related articles for article (PubMed ID: 21707483)
1. Sphingolipid metabolism and drug resistance in hematological malignancies.
Gouaze-Andersson V; Cabot MC
Anticancer Agents Med Chem; 2011 Nov; 11(9):891-903. PubMed ID: 21707483
[TBL] [Abstract][Full Text] [Related]
2. The Onus of Sphingolipid Enzymes in Cancer Drug Resistance.
Morad SAF; Cabot MC
Adv Cancer Res; 2018; 140():235-263. PubMed ID: 30060811
[TBL] [Abstract][Full Text] [Related]
3. Glycosphingolipids and drug resistance.
Gouaze-Andersson V; Cabot MC
Biochim Biophys Acta; 2006 Dec; 1758(12):2096-103. PubMed ID: 17010304
[TBL] [Abstract][Full Text] [Related]
4. Regulation of autophagy by sphingolipids.
Bedia C; Levade T; Codogno P
Anticancer Agents Med Chem; 2011 Nov; 11(9):844-53. PubMed ID: 21707487
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains.
Hinrichs JW; Klappe K; van Riezen M; Kok JW
J Lipid Res; 2005 Nov; 46(11):2367-76. PubMed ID: 16150833
[TBL] [Abstract][Full Text] [Related]
7. Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].
Loughran TP; Wang HG
Anticancer Agents Med Chem; 2011 Nov; 11(9):780-1. PubMed ID: 22023044
[No Abstract] [Full Text] [Related]
8. The involvement of sphingolipids in multidrug resistance.
Sietsma H; Veldman RJ; Kok JW
J Membr Biol; 2001 Jun; 181(3):153-62. PubMed ID: 11420602
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.
Loh KC; Baldwin D; Saba JD
Anticancer Agents Med Chem; 2011 Nov; 11(9):782-93. PubMed ID: 21707493
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
[TBL] [Abstract][Full Text] [Related]
11. The role of ABC transporters in clinical practice.
Leonard GD; Fojo T; Bates SE
Oncologist; 2003; 8(5):411-24. PubMed ID: 14530494
[TBL] [Abstract][Full Text] [Related]
12. The MRP family and anticancer drug metabolism.
Suzuki T; Nishio K; Tanabe S
Curr Drug Metab; 2001 Dec; 2(4):367-77. PubMed ID: 11766988
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
14. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
16. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
17. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
18. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
19. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives.
Fusi F; Saponara S; Valoti M; Dragoni S; D'Elia P; Sgaragli T; Alderighi D; Kawase M; Shah A; Motohashi N; Sgaragli G
Curr Drug Targets; 2006 Aug; 7(8):949-59. PubMed ID: 16918323
[TBL] [Abstract][Full Text] [Related]
20. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
